

Enantiopure (9-Anthryl)(2-piperidyl)- and (9-Anthryl)(2-pyridyl)methanols – Their Use as Chiral Modifiers for Heterogeneous Hydrogenation of Keto Esters over Pt/Al₂O₃

Arlette Solladié-Cavallo,^[a] Claire Marsol,^[a] Khalid Azyat,^[a] Marin Roje,^[b] Christopher Welch,^[c] Jennifer Chilenski,^[c] Philippe Taillasson,^[d] and Hugues D'Orchymont^[e]

Keywords: Amino alcohols / Chiral resolution / Chiral modifiers / Hydrogenation

A route toward the synthesis of the *erythro* isomer of (9-anthryl)(2-piperidyl)methanol is presented as well as resolution and assignment of the structure (through NMR). The use of both the *erythro* and *threo* enantiopure isomers of this new amino alcohol, and its precursor [(9-anthryl)(2-pyridyl)methanol], as chiral modifiers for the Pt/Al₂O₃ hydrogenation of ethyl lactate showed that the *erythro* isomer is not necessa-


rily the most efficient chiral modifier. This is probably because of the 9-anthryl group. The enantioselectivities that this compound provides are not, as one would expect, higher than those observed with the naphthyl group.

(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)

Introduction

Asymmetric heterogeneous hydrogenation of α -keto esters over supported platinum catalysts with the use of cinchona alkaloids (Orito reaction^[1]) has been known for about thirty years and has been the subject of numerous reviews.^[2] When we started our work in this field in 1998,^[3] it was already known that cinchonidine **1** was the most efficient chiral modifier^[2] and apart from cinchonidine or cinchonine derivatives^[4] the only different modifiers tested were type **3** amino alcohols (1994)^[5] and type **4** amines (1995).^[6a,6b] Our target was then amino alcohol **5a**^[3] which had the same –CH(OH)–CH(N)– link as cinchona alkaloids and one chiral carbon less. Moreover, both enantiomers of both the *erythro* and *threo* diastereomers could be available which would provide straightforward conclusions. With the use of **5a**, for the first time we clearly showed (2001) that the *erythro* isomer was a more efficient chiral modifier than the *threo* isomer^[3] and almost as efficient as

cinchonidine **1** (which is also an *erythro* isomer). Until 2002, it also seemed that the anthryl group had a tendency to provide higher enantioselectivities than the naphthyl group (when located on the carbon bearing the hydroxy



[a] Laboratoire de Stéréochimie Organométallique, ECPM/Université Louis Pasteur, 25 rue Becquerel, 67087 Strasbourg Cedex 02, France
Fax: +33-3-90242706
E-mail: cavallo@chimie.u-strasbg.fr

[b] Laboratory for Stereoselective Catalysis and Biocatalysis, Department of Organic Chemistry and Biochemistry, Ruder Bošković Institute, Bijenička 54, 10000 Zagreb, Croatia

[c] Merck & Co., Inc., Rahway, NJ 07065, USA

[d] Sylachim-Finorga, 38670 Chasse sur Rhone, France


[e] Sanofi-Synthelabo Recherche, 67080 Strasbourg, France

group). Therefore, we decided to synthesize and study *erythro* and *threo* amino alcohols **5b**. By the time this work was completed, other results appeared that dealt with the comparison of anthryl and naphthyl groups in the case of amines **4**^[6c–6e] and amino alcohols **6**.^[7]

We present here the synthesis and resolution of both the *erythro* and *threo* diastereomers of anthryl amino alcohol **5b**, a synthesis of the pure *erythro* isomer (lower overall yield but no difficulty with the separation of diastereomers), the use of **5b** as a chiral modifier for the heterogeneous hydrogenation of ethyl pyruvate over Pt/Al₂O₃, as well as the use of precursor **7** to test the effect of the possible in situ hydrogenation of **7** into **5b** during hydrogenation of pyruvate.

Synthesis

Condensation of the 9-anthryl Grignard reagent with 2-pyridinecarboxaldehyde proceeded smoothly in THF to provide anthrylpyridyl alcohol **7** in 80% yield (Scheme 1). Heterogeneous hydrogenation of **7** with the use of PtO₂ (from Aldrich) in EtOH/HCl (1 equiv.)^[8,9] then provided pure *erythro* **5b-II** in 40% yield (**5b-I**/**5b-II** = 0/100).




Scheme 1.

It is worth noting that *threo* isomer **5b-I** (necessary for structure determination) can be obtained (as the major isomer) from formamidine **8**, Scheme 2, by following Meyers' procedures,^[10,11] (overall yield 50%, after chromatographic purification).

Table 1. NMR spectroscopic data for *threo* and *erythro* configurations.

Amino alcohol	³ J _{1–2} CDCl ₃ [Hz]	Δ ³ J [Hz]	δ(1-H) [ppm]	Configuration
5-I (Ar = Ph)	7.5	2.5	4.36	<i>threo</i> ^[a]
5-II (Ar = Ph)	5.0		4.56	<i>erythro</i> ^[a]
(1 <i>S</i> ,2 <i>S</i>)-Pseudoephedrine	8.2	4.3		<i>threo</i> ^[a]
(1 <i>R</i> ,2 <i>S</i>)-Ephedrine	3.9			<i>erythro</i> ^[a]
5a-I (67%)	6.0	2	5.24	<i>threo</i> ^[a]
5a-II (33%)	4.0		5.44	<i>erythro</i> ^[a]
5b-I (80%)	9.5	2	6.03	<i>threo</i>
5b-II (20%)	7.5		6.10	<i>erythro</i>

[a] Known compounds, cf. refs.^[12,13]



Scheme 2.

The ratios of **I/II** have been determined with the use of the 1-H proton doublets (between δ = 6.0 ppm and 6.2 ppm, Table 1).

Determination of *threolerythro* Structure of **5b-I** and **5b-II**


threolerythro Structure from NMR

In amino alcohols having the CH(OH)–CH(NH) system and of known structure, Table 1, the *erythro* isomer has the smallest coupling constant. Therefore, the *erythro* structure has been assigned to isomer **5b-II**, which exhibits the smallest coupling constant: 7.5 Hz versus 9.5 Hz for isomer **5b-I**.

Moreover, the 1-H doublets in the *erythro* isomers are always the most deshielded, which is the case here too (δ = 6.10 ppm compared to δ = 6.03 ppm for the *threo* isomer in this case).

erythro Structure from Model

The *erythro* structure assigned by NMR to isomer **II**, the only isomer obtained from hydrogenation over PtO₂, is consistent with the model shown in Scheme 3, as it is reasonable to postulate that the hydrogen (located on the catalyst surface) approaches from the less hindered side of the H-bonded **C1** conformer of substrate **7** (1-H side).



Scheme 3.

Resolution of Piperidyl Alcohol **5b-I** and **5b-II**

Diastereomeric separation of the *threo* isomer from the *erythro* isomer was performed first by preparative supercritical fluid chromatography with a Chromegabond Amine column (25 cm × 23 mm ID, 5 μm 60 Å, ES Industries) at a flow rate of 50 mL/min with a mobile phase of 25% methanol in carbon dioxide (100 bar outlet pressure) with UV detection at 257 nm.


Analytical separation of racemic pure *threo* isomer **5b-I** was further performed with a CHIRALCEL OD-RH column (150 × 4.6 mm, 5 μm) with acetonitrile/ethanolamine, 100:0.1, as the mobile phase (flow rate = 0.5 mL/min) and UV detection at 235 nm.

On a preparative scale, a CHIRALCEL OD column (250 × 50 mm, 20 μm) and the same mobile phase (100 mL/min) were then used. After recrystallization from acetonitrile (to completely remove ethanolamine as seen from ¹H NMR) of the two fractions having the highest *ee*, the specific rotations of enantiomers *threo* **5b-II** and *threo* **5b-I2** were determined: *threo* **5b-I1**: [*a*]_D = +11.0 (*c* = 0.45, CHCl₃), *ee* = 99%; *threo* **5b-I2**: [*a*]_D = −10.8 (*c* = 0.50, CHCl₃), *ee* = 99%.

The *erythro* isomer (**5b-II**) was obtained pure and the enantiomers were then preparatively obtained by supercritical fluid chromatography with the use of a CHIRALPAK AD column (250 × 20 mm, 10 μm) at a flow rate of 50 mL/min with a mobile phase of 16% methanol (containing 25 mM of isobutylamine) in carbon dioxide (100 bar outlet pressure) with UV detection at 257 nm, with the isolation of two fractions: *erythro* **5b-III** negative CD at 263 nm, *ee* = 99%; *erythro* **5b-II2** positive CD at 263 nm, *ee* = 99%. [*a*]_D = +17 (*c* = 0.24, CHCl₃).

Resolution of Pyridyl Alcohol 7

Analytical separation of *rac*-**7** was performed with a CHIRALCEL OD column (250 × 4.6 mm, 10 μm) with hexane/EtOH/diethylamine, 8:2:0.5, as the mobile phase (flow rate = 1 mL/min) and UV detection at 254 nm. On a preparative scale, a CHIRALCEL OD column (0.46 × 25 cm, 10 μm) and the same mobile phase (120 mL/min) were used with the isolation of two fractions: (−)-**7**, chemical purity >95% (by 400 MHz ¹H NMR). [*a*]_D = −171 (*c* = 0.36, CHCl₃), *ee* = 100% (from analytical chromatography); (+)-**7**, chemical purity >95% (by 400 MHz ¹H NMR). [*a*]_D = +97 (*c* = 0.37, CHCl₃), *ee* = 57% (from specific rotation).



Asymmetric Pt/Al₂O₃ Hydrogenation of Ethyl Pyruvate

After hydrogenation and distillation, the enantiomeric excesses of the ethyl lactate samples were determined by gas chromatography with a Cyclodex-B capillary column (30 m) with the use of an HP 5890 GC-FID instrument and the *ee* values were reproducible within 1%.

The well-defined catalyst 5% Pt/Al₂O₃ 4759 from Engelhard was activated before use (3 h, 300 °C, under H₂ flow); AcOH was used as the solvent. The reactions were run at room temperature for 2 h with stirring at a rate of ca. 500 rpm, and the pyruvate, purchased from Aldrich, was distilled before used. The results are given in Table 2.

Table 2. Ethyl pyruvate hydrogenation over 5% Pt/Al₂O₃ at room temperature for 2 h.

Modifier	Conversion [%]	(<i>R</i>)/(<i>S</i>)	<i>ee</i> [%]
None	13	—	—
(+)- 5b-II2 <i>erythro</i>	100	68:32	36
(−)- 5b-III <i>erythro</i>	100	32.5:67.5	35
(−)- 5b-I2 <i>threo</i>	100	27:73	46
(+)- 5b-I1 <i>threo</i> ^[a]	100	73.5:26.5	47
(−)- 7	100	37:63	26

[a] Cf. ref.^[3]

It is worth noting that, contrary to the cinchona alkaloids generally used, **5b-I1** and **5b-I2** (as well as **5b-III** and **5b-II2**) are true enantiomers; therefore, the samples of **5b-I1** and **5b-I2** (as well as **5b-III** and **5b-II2**) that were used that have identical enantiomeric purities (cf. above) provide identical (*R*)/(*S*) ratios to ethyl lactate, within the reproducibility of the method used, for the determination of these ratios (compare 68:32 with 32.5:67.5 and 27:73 with 73.5:26.5). It appears that (*S*)-lactate is obtained from (−)-**5b-II** (*erythro*) and (−)-**5b-I** (*threo*) while (+)-**5b-II** and (+)-**5b-I** provide (*R*)-lactate. It is also worth noting that the *threo* isomers provide slightly higher enantioselectivities than the *erythro* isomers (46–47% versus 35–36% *ee*).

Precursor **7**, which under these conditions undergoes slow hydrogenation^[14] into desired **5b-II**, is less efficient probably because hydrogenation of pyruvate is too rapid and that **7** is a less efficient chiral modifier.

Conclusions

These results show that the *erythro* isomer is not necessarily the most efficient chiral modifier as was suggested from previous results obtained by using compound **5a**^[3] and cinchona alkaloids^[4,15] (Table 3).

Table 3. Hydrogenation of ethyl pyruvate with the use of various chiral modifiers.

Modifier	Conversion [%]	(<i>R</i>)/(<i>S</i>)	<i>ee</i> [%]
Cinchonidine (9 <i>R</i> ,8 <i>S</i>) <i>erythro</i>	100	93.5:6.5	87
Epiquinidine (<i>threo</i>) ^[a]	?	1:1	0
(−)-(1 <i>R</i> ,2 <i>S</i>)- 5a-II <i>erythro</i>	100	86.5:13.5	73
(+)-(1 <i>S</i> ,2 <i>R</i>)- 5a-II <i>erythro</i> ^[b]	100	14:86	72
(−)- 5a-I <i>threo</i>	100	27:73	46
(+)- 5a-I <i>threo</i> ^[b]	67	67.5:32.5	35 ^[c]
(+)- 6a -(1 <i>S</i> ,2 <i>R</i>) <i>erythro</i> ^[d]	—	6:94	88
(+)- 6b -(1 <i>S</i> ,2 <i>R</i>) <i>erythro</i> ^[d]	—	10.5:89.5	79

[a] Cf. ref.^[15] [b] Cf. ref.^[3], note that the absolute configuration of *erythro* **5a-II** was determined from the stereo-outcome of the hydrogenation of pyruvate and confirmed by VCD (ref.^[13]). [c] This sample of the *threo* isomer that was used contained 1.8% of one enantiomer of the *erythro* isomer (ref.^[13]). [d] Cf. ref.^[7]

The results also corroborate that the anthryl group is not necessarily a more efficient modifier than the naphthyl group, and it may provide lower enantioselectivities for both *erythro* and *threo* isomers as in the case of type **5** amino alcohols (compare Table 2 and Table 3) or compara-

ble enantioselectivities in the case of type **6** *erythro* amino alcohol (Table 3).

As in the case of (–)-**5a-II**, for which the (1*R*,2*S*) configuration was determined from the stereo-outcome of the reaction (pyruvate hydrogenation) and corroborated by VCD, one could postulate from the stereo-outcome of the pyruvate hydrogenation reaction that (+)-**5b-II**, which also provides (*R*)-lactate, has the (1*R*,2*S*) configuration.

Experimental Section

General Procedure for Anthryl Grignard Addition onto 2-Pyridinecarboxaldehyde: It is worth noting that the 9-anthryl grignard formed from 9-bromoanthracene must be generated in THF heated at reflux. A solution of bromoanthracene (3.36 g, 13 mmol) in anhydrous THF (80 mL) was added dropwise whilst stirring to a suspension of Mg (0.31 g, 13 mmol) in anhydrous THF (30 mL) and 1,2-dibromoethane (0.2 mL). The mixture was heated at reflux and stirring was maintained until all of the Mg disappeared. After cooling to room temperature, a solution of 2-pyridinecarboxaldehyde (0.7 g, 6.5 mmol) in anhydrous THF (30 mL) was added dropwise whilst stirring overnight. Then, a saturated aqueous solution of NH₄Cl was added, THF was evaporated under vacuum, and the aqueous phase was extracted with CH₂Cl₂ (5 × 20 mL). The combined organic phases were dried with Na₂SO₄, the solvent removed under reduced pressure, and the amino alcohol isolated and purified by chromatography on silica gel (ether/hexane, 3:2). **7**: ¹H NMR (300 MHz, CDCl₃): δ = 5.9 (br. s, 1 H), 6.72 (d, ³J = 7.5 Hz, 1 H), 7.2 (dd, ³J = 7.5, 5 Hz, 1 H), 7.29 (s, 1 H), 7.44 (m, 5 H), 8.02 (m, 2 H), 8.31 (m, 2 H), 8.49 (s, 1 H), 8.71 (d, ³J = 5 Hz, 1 H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 69.7, 120.8, 122.1, 124.8, 125.0, 127.2, 128.9, 129.3, 130.7, 131.8, 132.3, 137.0, 147.6, 161.8 ppm. C₂₀H₁₅NO (285.22): calcd. C 84.17, H 5.30; found C 84.00, H 5.42.

General Procedure for PtO₂ Hydrogenation: To a solution of **7** (0.2 g, 0.7 mmol) in EtOH (10 mL) in a glass tube that exactly fits inside of a stainless steel autoclave were added successively concentrated HCl (0.05 mL, 0.7 mmol) and PtO₂ (30 mg). After being purged twice (vacuum/H₂ admission), the mixture was stirred under 50 bar H₂ and at 0 °C for 6 h. The catalyst was filtered out, NaOH (1 equiv.) and H₂O (5 mL) were added, the mixture was extracted with CH₂Cl₂ (10 × 10 mL), the combined organic phases were dried with Na₂SO₄, the solvent was removed under vacuum, and the amino alcohol was then purified by chromatography on silica gel (ether/hexane, 9:1). *threo* **5b-I**: ¹H NMR (400 MHz, CDCl₃): δ = 0.81 (br. d, ³J = 12.0 Hz, 1 H, 2-H_a), 1.0 (m, 1 H, 3-H), 1.10 (br. q, 1 H, 2-H_a), 1.36 (m, 1 H, 4-H), 1.48 (m, 2 H, 3-H, 4-H), 2.69 (td, ²J = 12 Hz, ³J = 12 Hz, 2.5 Hz, 1 H, 5-H_a), 3.09 (br. d, ²J = 12 Hz, 1 H, 5-H_c), 3.52 (td, ³J = 9.5 Hz, 9.5 Hz and 4 Hz, 1 H, 1-H), 3.60 (br. s, 1 H), 6.03 (d, ³J = 9.5 Hz, 1 H), 7.47 (m, 4 H), 8.00 (m, 2 H), 8.40 (s, 1 H), 8.72 (br., 2 H)^[6] ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 24.5, 26.0, 29.4, 46.7, 62.0, 73.5, 125.1, 125.2, 125.7, 128.4, 129.6, 130.7, 132.0, 133.8 ppm. C₂₀H₂₁NO (291.22): calcd. C 82.44, H 7.26; found C 81.79, H 7.34. *erythro* **5b-II**: All signals overlapped with those of *threo* **5b-I**, except: δ = 2.72 (br. t, ²J = ³J = 12 Hz, 1 H, 5-H_a) and 6.10 (d, ³J = 7.5 Hz, 1 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 24.1, 25.2, 28.2, 46.6, 62.2, 73.7, 124.8, 125.7, 128.4, 129.1, 130.2, 131.6, 132.1 ppm.

General Procedure for Aldolization of Formamidine **8:** To a solution of piperidine formamidine **8** (2.0 g, 11.88 mmol, 1.0 equiv.) in an ether/THF mixture (15:4 mL) was added (at –78 °C) *tert*-butyllith-

ium (1.7 M, 8.5 mL, 14.25 mmol, 1.2 equiv.). The solution was stirred at –20 °C for 1 h, which resulted in the formation of a white precipitate. The reaction mixture was cooled to –78 °C, the desired aldehyde (1.1 equiv.) added, and the mixture slowly warmed up to 0 °C over 5 h. The solution was poured into 10% HCl (30 mL) and extracted with diethyl ether (2 × 10 mL). The aqueous layer was then made basic (pH 12) with 20% NaOH and extracted several times with dichloromethane. The combined organic phases were then concentrated under vacuum. A solution of the resulting crude product in MeOH (25 mL) and water (4 mL) and KOH (4 g) was heated at 60 °C for 24 h. After cooling, the mixture was extracted with dichloromethane (5 × 15 mL). The combined dichloromethane phases were dried with Na₂SO₄, the solvents removed under reduced pressure, and the amino alcohol isolated and purified by chromatography on silica gel (CH₂Cl₂/MeOH, 4:1).

General Procedure for Pt/Al₂O₃ Hydrogenation: A mixture of ethyl pyruvate (5 mL, 3500 equiv.) and the desired chiral modifier (1 equiv.), stirred for 30 min before used, was poured into a glass tube that exactly fits inside of a stainless steel autoclave. AcOH (10 mL) and the activated catalyst (50 mg, 1 equiv. in Pt) were then added successively. After being closed tightly, the device was purged three times (through successive vacuum-H₂ admission), the H₂ pressure was fixed at 40 bar, and the mixture was stirred for 2 h. The conversion was determined by using ¹H NMR of the crude products, then ethyl lactate was separated from other components through distillation and the *ee* was determined by chromatography (cf. text above). **9**: ¹H NMR (300 MHz, CDCl₃): δ = 1.23 (t, ³J = 7 Hz, 3 H), 1.35 (d, ³J = 7 Hz, 3 H) 3.15 (br. s, 1 H, OH), 4.17 (2 H, CH₂ and 1 H, CH overlapped q).

Resolution of Piperidyl Alcohols **5b-I** and **5b-II** and Pyridyl Alcohol


7: Diastereomeric separation of the *threo* isomer from the *erythro* isomer was first necessary (cf. above). Analytical separation of racemic pure *threo* isomer **5b-I** was then performed further with a CHIRALCEL OD-RH (150 × 4.6 mm, 5 μm) column with acetonitrile/ethanolamine, 100:0.1 as the mobile phase (flow rate = 0.5 mL/min), the chromatographic parameters obtained are: *R*_{t1} = 9.15 min, *R*_{t2} = 11.04 min, *k*'₁ = 1.54, *k*'₂ = 2.07, α = 1.34. Then, on a preparative scale, 483 mg of *rac*-**5b-I** was resolved by using a larger CHIRALCEL OD column (250 × 50 mm, 20 μm) and the same mobile phase (100 mL/min), with isolation of three fractions whose enantiomeric purities were determined by using the analytical conditions (93% of the starting material was recovered): 250 mg (52%) *threo*: enantiomer 1 (**5b-II**), chemical purity = 95%, *ee* = 100%; 90 mg (19%) *threo*: enantiomer 2 (**5b-I2**), *ee* = 86.8%; 109 mg (22%) *threo*: enantiomer 2 (**5b-I2**), chemical purity = 94%, *ee* = 98.5%. The enantiomers of **5b-II** were preparatively obtained by supercritical fluid chromatography by using a CHIRALPAK® AD column (250 × 20 mm, 10 μm) from Chiral Technologies, Inc. and recovery of 81% of the starting material (the enantiomeric purities of the fractions have been determined by using the analytical conditions): *erythro* **5b-III** (70 mg), first eluted: *R*_t = 16.21 min, negative CD at 263 nm, *ee* = 99%; *erythro* **5b-II2** (108 mg), second eluted: *R*_t = 17.31 min, positive CD at 263 nm, *ee* = 99%. Analytical and preparative separation of *rac*-**7** were performed with CHIRALCEL OD columns with different sizes (either 250 × 4.6 mm, 10 μm or 0.46 × 25 cm, 10 μm) and the same mobile phase. The analytic chromatographic parameters obtained are: *R*_{t1} = 14.50 min, *R*_{t2} = 16.00 min. On the preparative scale, 167 mg of *rac*-**7** was resolved with isolation of two fractions and recovery of 74% of the starting material (the enantiomeric purities of the fractions have been determined by using the analytical conditions): 52 mg enantiomer (–)-**7**, chemical purity >95% (by 400 MHz ¹H

NMR); 71 mg enantiomer (+)-**7**, chemical purity >95% (by 400 MHz ^1H NMR).

Acknowledgments

We are grateful to Region Alsace and to CNRS for a grant to C. M. (BDI), to Ministère de L'Enseignement Supérieur et de la Recherche for a grant (MNERT) to K. A. and Ministère des Affaires Étrangères for a grant to M. R.

- [1] Y. Orito, S. Imai, S. Niwa, *J. Chem. Soc. Jpn.* **1979**, 1118; Y. Orito, S. Imai, S. Niwa, *J. Chem. Soc. Jpn.* **1980**, 670.
- [2] a) T. Bürgi, A. Baiker, *Acc. Chem. Res.* **2004**, 37, 909 and included references for previous reviews; b) A. Baiker, *Catal. Today* **2005**, 100, 159 and included references for previous reviews.
- [3] a) C. Marsol, Ph.D. Dissertation, **2001** (started **1998**), Strasbourg University, France; b) Second European Catalysis Symposium (**2001**, Pise-Italy); c) A. Solladié-Cavallo, C. Marsol, F. Garin, *Tetrahedron Lett.* **2002**, 43, 4733–4735; d) K. Azyat, Ph.D. Dissertation **2005** (started **2002**), Strasbourg University, France.
- [4] a) H. Blazer, H. P. Jallet, J. Wiehl, *J. Mol. Catal.* **1991**, 68, 215; b) P. B. Wells, A. G. Wilkinson, *Top. Catal.* **1998**, 5, 39; c) S. Diezi, T. Mallat, A. Szabo, A. Baiker, *J. Catal.* **2004**, 228, 162; d) O. J. Sonderegger, G. M.-W. Ho, T. Bürgi, A. Baiker, *J. Mol. Catal. A* **2005**, 229, 19; e) M. Bartok, M. Sutyinszki, I. Bucsí, K. Felföldi, G. Szöllösi, F. Bartha, T. Bartok, *J. Catal.* **2005**, 231, 33; f) I. Busygin, E. Toukoniiitty, R. Leino, D. Yu. Murzin, *J. Mol. Catal. A* **2005**, 236, 227; g) M. Bartok, K. Balazsik, I. Bucsí, G. Szöllösi, *J. Catal.* **2006**, 239, 74.
- [5] G. Wang, T. Heinz, A. Pfaltz, B. Minder, T. Mallat, A. Baiker, *J. Chem. Soc., Chem. Commun.* **1994**, 2047.
- [6] a) T. Heinz, G. Wang, A. Pfaltz, B. Minder, M. Schürch, T. Malat, A. Baiker, *J. Chem. Soc., Chem. Commun.* **1995**, 1421; b) B. Minder, M. Schürch, T. Mallat, A. Baiker, T. Heinz, A. Pfaltz, *J. Catal.* **1996**, 160, 261. See also; c) A. Solladié-Cavallo, C. Marsol, C. Suteu, F. Garin, *Enantiomer* **2001**, 6, 245; d) S. Diezi, M. Hess, E. Orglmeister, T. Mallat, A. Baiker, *J. Mol. Catal. A* **2005**, 239, 49; e) E. Orglmeister, T. Bürgi, T. Mallat, A. Baiker, *J. Catal.* **2005**, 232, 137.
- [7] C. Exner, A. Pfaltz, M. Studer, H. U. Blaser, *Adv. Synth. Catal.* **2003**, 345, 1253.
- [8] T. S. Hamilton, R. Adams, *J. Am. Chem. Soc.* **1928**, 50, 2260.
- [9] A. Solladié-Cavallo, M. Roje, A. Baram, V. Sunjić, *Tetrahedron Lett.* **2003**, 44, 8501–8503.
- [10] A. I. Meyers, W. Ten Hoeve, *J. Am. Chem. Soc.* **1980**, 102, 7125.
- [11] A. I. Meyers, P. D. Edwards, W. F. Rieker, T. R. Bailey, *J. Am. Chem. Soc.* **1984**, 106, 3270.
- [12] a) J. B. LaPidus, J. J. Fauley, *J. Org. Chem.* **1971**, 36, 3065; b) A. I. Meyers, P. D. Edwards, T. R. Bailey, G. E. Jagdmann, *J. Org. Chem.* **1985**, 50, 1019.
- [13] A. Solladié-Cavallo, C. Marsol, M. Yaakoub, K. Azyat, A. Klein, M. Roje, C. Suteu, T. B. Freedman, X. Cao, L. A. Nafie, *J. Org. Chem.* **2003**, 68, 7308–7315.
- [14] Under these conditions, **7** provides only 6% of **5b-II**.
- [15] a) H. U. Blaser, H. P. Jallet, W. Lottenbach, M. Studer, *J. Am. Chem. Soc.* **2000**, 122, 12675; b) K. Szöri, M. Sutyinszki, K. Felföldi, M. Bartok, *Applied Catal. A: General* **2002**, 237, 275.
- [16] This broad singlet corresponds to protons 1-H and 1'-H of the anthryl group which coalesce at the probe temperature. A decrease in the temperature leads to two doublets having different chemical shifts. This behavior has also been observed for α -(9-anthryl)ethylamine: cf. C. Marsol, Ph.D. Dissertation, **2001**, Strasbourg, France.



Received: August 18, 2006
Published Online: December 8, 2006